<div id="readability-page-1"><div><p><span>Daly James M, Director of Acadia Pharmaceuticals Inc [ACAD], filed a Form 144 on November 10, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>11/10/25</span></td></tr><tr><td><span>Shares</span></td><td><span>30,000</span></td></tr><tr><td><span>Broker</span></td><td><span>Morgan Stanley Smith Barney LLC</span></td></tr></tbody></table></div><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ACAD

<p>Daly James M, Director of Acadia Pharmaceuticals Inc [ACAD], has filed a Form 144 with the SEC on November 10, 2025, to sell 30,000 shares of restricted securities. The sale is permitted within 90 days following the filing. The broker for this transaction is Morgan Stanley Smith Barney LLC.</p>

Dir Daly Files To Sell 30,000 Of Acadia Pharmaceuticals Inc [ACAD]